Management Targeted Genetic Evaluation of an Idiopathic Neuropathy Cohort Through ATTRv Amyloidosis Screening
Precision medicine on the molecular level with genetic testing in the identification of specific neuropathies may provide clinicians with more detailed information for developing a more direct therapeutic and treatment modality for better-targeted management. Further investigation is needed to expand on the knowledge and understanding of the clinical relevance surrounding the alterations found in the genetic evaluation of idiopathic neuropathy.
Authors
- C. A. Brock (ORCID: https://orcid.org/0000-0002-4033-4668)
- Santiago Andrés Díaz
- Jeffrey Gelblum
- Meghan C. Towne (ORCID: https://orcid.org/0000-0001-9460-2368)
- Kristy A Fisher (ORCID: https://orcid.org/0000-0002-2051-264X)
- Niraja Suresh
Institutions
- University of South Florida (US)
- Aventura Hospital and Medical Center (US)
- Ambry Genetics (United States) (US)
- University of South Alabama (US)
Publication Details
- Journal
- HCA Healthcare Journal of Medicine
- Published
- 2024-08-30
- DOI
- https://doi.org/10.36518/2689-0216.1557
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00